Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

被引：28
|
作者：
Mukherjee, Sarbajit [1 ]
Ibrahimi, Sami [1 ]
Khalid, Bilal [1 ]
Roman, Darwin [2 ]
Zhao, Daniel [3 ]
Aljumaily, Raid [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Hematol Oncol, Oklahoma City, OK USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 03期
关键词：
D O I：
10.1177/1078155218771152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [31] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    Patrinely, James Randall, Jr.
    Dewan, Anna K.
    Johnson, Douglas B.
    BIODRUGS, 2020, 34 (04) : 495 - 503
  • [32] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    James Randall Patrinely
    Anna K. Dewan
    Douglas B. Johnson
    BioDrugs, 2020, 34 : 495 - 503
  • [33] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Yuegang Li
    Yuwei Du
    Chi Xue
    Pei Wu
    Nan Du
    Guolian Zhu
    Huimian Xu
    Zhi Zhu
    BMC Gastroenterology, 22
  • [34] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Li, Yuegang
    Du, Yuwei
    Xue, Chi
    Wu, Pei
    Du, Nan
    Zhu, Guolian
    Xu, Huimian
    Zhu, Zhi
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [35] Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
    Nishioka, Naoya
    Uchino, Junji
    Hirai, Soichi
    Katayama, Yuki
    Yoshimura, Akihiro
    Okura, Naoko
    Tanimura, Keiko
    Harita, Sachi
    Imabayashi, Tatsuya
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
  • [36] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [37] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [38] Exosomal PD-L1 and T lymphocyte status predict the effect of anti-PD-1 therapy
    Qu, Xiujuan
    Zhang, Chaoxu
    Fan, Yibo
    Che, Xiaofang
    Liu, Yunpeng
    CANCER RESEARCH, 2019, 79 (13)
  • [39] IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study
    Yuan, Wenli
    Deng, Deyao
    Li, Hanyu
    Hu, Xinghui
    Shang, Xueqin
    Hou, Xia
    Jiang, Hongchao
    He, Hongchun
    ONCOTARGETS AND THERAPY, 2021, 14 : 3051 - 3062
  • [40] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato
    Noriyuki Okonogi
    Takashi Nakano
    International Journal of Clinical Oncology, 2020, 25 : 801 - 809
12345